早產預防和管理市場機會、成長動力、行業趨勢分析和 2025 - 2034 年預測

2024 年全球早產預防和管理市場價值為 18 億美元，預計 2025 年至 2034 年期間的複合年成長率為 7.7%。 這一顯著成長是由多種因素推動的，包括早產率上升、醫療技術的進步、產婦危險因素患病率增加以及對改善新生兒護理的高度重視。

市場涵蓋一系列旨在預防和管理早產的治療方法，包括子宮收縮抑制劑治療、黃體酮治療、抗生素治療、皮質類固醇治療、肝素預防治療和其他治療方案。其中，孕酮療法預計將引領市場，年複合成長率為 8%，到 2034 年將產生 15 億美元的市場價值。 孕酮已被廣泛研究並被證明可以顯著降低早產風險，特別是對於有自然早產史或高風險的女性。它已被證明能有效預防早產，特別是對於子宮頸短或多胎妊娠的婦女，因此被廣泛採用作為主要預防措施。

市場也根據給藥途徑進行細分，包括腸外給藥、口服給藥和外用給藥。預計腸外給藥領域將經歷強勁成長，預計複合年成長率為 7.6%，到 ​​2034 年將達到 27 億美元。這種方法對於高風險妊娠至關重要，因為它繞過了消化系統，確保了更一致和可控的劑量，這使其成為臨床環境中的首選方案。

在美國，2024 年早產預防和管理市場價值為 6.716 億美元，預計 2025 年至 2034 年期間的複合年成長率為 7.2%。這項挑戰推動了對先進療法、治療方法和創新解決方案的需求。此外，美國在母胎醫學研究領域仍然處於全球領先地位，為預防和管理早產的尖端技術和實踐的發展做出了貢獻。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 早產盛行率不斷上升
    • 孕產婦和胎兒照護的進步
    • 提高對早產危險因子的認知
    • 政府措施和資金不斷增加
  • 產業陷阱與挑戰
    • 副作用和安全問題
    • 來自學名藥的潛在競爭
• 成長潛力分析
• 監管格局
• 技術格局
• 管道分析
• 差距分析
• 波特的分析
• PESTEL 分析
• 未來市場趨勢
• 價值鏈分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按治療類型，2021 – 2034 年

• 主要趨勢
• 黃體素治療
• 皮質類固醇治療
• 子宮收縮抑制劑治療
• 抗生素治療
• 肝素預防治療
• 其他治療類型

第 6 章：市場估計與預測：按管理路線，2021 年至 2034 年

• 主要趨勢
• 腸外
• 口服
• 主題

第 7 章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 實體店面
• 電子商務

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• AMAG Pharmaceuticals
• Ferring Pharmaceutical
• Merck
• Obseva
• Pfizer
• Takeda Pharmaceutical

The Global Preterm Birth Prevention And Management Market was valued at USD 1.8 billion in 2024 and is projected to expand at a CAGR of 7.7% from 2025 to 2034. This remarkable growth is driven by several factors, including rising rates of preterm births, advancements in medical technology, an increasing prevalence of maternal risk factors, and a heightened focus on improving neonatal care.

The market encompasses a range of therapies designed to prevent and manage preterm births, including tocolytic therapy, progesterone therapy, antibiotics therapy, corticosteroid therapy, heparin prophylaxis therapy, and other treatment options. Among these, progesterone therapy is expected to lead the market, growing at a CAGR of 8% and generating USD 1.5 billion by 2034. Progesterone has been extensively studied and proven to significantly reduce the risk of preterm births, particularly in women with a history of spontaneous preterm deliveries or those at high risk. Its proven effectiveness in preventing early labor, especially for women with a short cervix or multiple pregnancies, contributes to its widespread adoption as a primary preventative measure.

The market is also segmented by the route of administration, which includes parenteral, oral, and topical options. The parenteral administration segment is anticipated to experience robust growth, with a projected CAGR of 7.6%, reaching USD 2.7 billion by 2034. Parenteral administration, especially via intravenous (IV) or intramuscular (IM) routes, offers more rapid and efficient delivery of critical drugs like progesterone or tocolytics. This method is essential for high-risk pregnancies, as it bypasses the digestive system, ensuring more consistent and controlled dosing, which makes it a preferred option in clinical settings.

In the U.S., the preterm birth prevention and management market was valued at USD 671.6 million in 2024 and is expected to grow at a CAGR of 7.2% between 2025 and 2034. The U.S. faces a relatively high rate of preterm births compared to other developed nations, creating a pressing need for effective strategies to prevent and manage these early deliveries. This challenge drives the demand for advanced therapies, remedies, and innovative solutions. Furthermore, the U.S. remains a global leader in maternal-fetal medicine research, contributing to the development of cutting-edge technologies and practices designed to prevent and manage preterm births.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of preterm birth
    • 3.2.1.2 Advancements in maternal and fetal care
    • 3.2.1.3 Increased awareness of preterm birth risk factors
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and safety concerns
    • 3.2.2.2 Potential competition from generic drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Future market trends
• 3.11 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Progesterone therapy
• 5.3 Corticosteroid therapy
• 5.4 Tocolytic therapy
• 5.5 Antibiotics therapy
• 5.6 Heparin prophylaxis therapy
• 5.7 Other therapy types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Oral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Brick and mortar
• 7.3 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 AMAG Pharmaceuticals
• 9.3 Ferring Pharmaceutical
• 9.4 Merck
• 9.5 Obseva
• 9.6 Pfizer
• 9.7 Takeda Pharmaceutical